Is GPnMB the Achilles' heel of Mo-MDSC while marking their suppressive activity?

Mario P. Colombo

doi:10.1158/1078-0432.CCR-18-2334

Is GPnMB the Achilles' heel of Mo-MDSC while marking their suppressive activity?

Mario P. Colombo

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Glycoprotein nonmetastatic B/DC-Hil/Osteoactivin on myeloid-derived suppressor cells impairs T lymphocytes through the binding of Syndecan-4, delineating a new checkpoint pair to be targeted perhaps in combination with PD-1/PD-L1 blockage.

Original language	English
Pages (from-to)	453-454
Number of pages	2
Journal	Clinical Cancer Research
Volume	25
Issue number	2
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-2334
Publication status	Published - Jan 15 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-18-2334

Cite this

@article{cc2b7a8132e341afbc69e8a18642514f,

title = "Is GPnMB the Achilles' heel of Mo-MDSC while marking their suppressive activity?",

abstract = "Glycoprotein nonmetastatic B/DC-Hil/Osteoactivin on myeloid-derived suppressor cells impairs T lymphocytes through the binding of Syndecan-4, delineating a new checkpoint pair to be targeted perhaps in combination with PD-1/PD-L1 blockage.",

author = "Colombo, {Mario P.}",

year = "2019",

month = jan,

day = "15",

doi = "10.1158/1078-0432.CCR-18-2334",

language = "English",

volume = "25",

pages = "453--454",

journal = "Clinical Cancer Research",

issn = "1078-0432",